ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
